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Bone tissue engineering is rapidly developing, thanks to the development of cell
biology and material science. The basic premise of tissue engineering is that lost
or damaged tissues can be regenerated by three-dimensional, porous, biodegradable
scaffolds and healthy progenitor cells which have been grafted to injured areas.
Poly-ε-caprolactone (PCL) is a polyester with chemico-physical characteristics
that can be made into an appropriate scaffold for bone engineering. Its mechanical
properties and tissue stability have been proven through many applications.
1,2 Rai.
et al. stated that the synergy of PCL that contained bioactive tricalcium phosphate
(TCP) and recombinant human bone morphogenetic protein-2 (rhBMP-2) is an
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Purpose: The aim of this study was to evaluate the survival, proliferation, and bone formation of dog mesenchymal
stem cells (dMSCs) in the graft material by using Polycaprolactone-tricalcium phosphate (PCL-TCP), auto-fibrin glue
(AFG), recombinant human bone morphogenetic protein-2 (rhBMP-2), and dMSCs after a transplantation to the
scapula of adult beagle dogs. Materials and Methods: The subjects were two beagle dogs. Total dose of rhBMP-2 on
each block was 10 µg with 50 µg/mg concentration. The cortical bone of the scapula of the dog was removed which
was the same size of PCL-TCP block (Osteopore International Pte, Singapore; 5.0×5.0×8.0 mm in size), and the
following graft material then was fixed with orthodontic mini-implant, Dual-top
® (Titanium alloy, Jeil Co. Seoul,
Korea). Four experimental groups were prepared for this study, Group 1: PCL-TCP + aFG; Group 2: PCL-TCP + aFG
+ dMSCs; Group 3: PCL-TCP + aFG + dMSCs + rhBMP-2; Group 4: PCL-TCP + aFG + dMSCs + rhBMP-2 + PCL
membrane. The survival or proliferation of dMSCs cells was identified with an extracted tissue through a fluorescence
microscope, H-E staining and Von-Kossa staining in two weeks and four weeks after the transplantation. Results:The
survival and proliferation of dMSCs were identified through a fluorescence microscope from both Group 1 and Group
2 in two weeks and four weeks after the transplantation. Histological observation also found that the injected cells were
proliferating well in the G2, G3, and G4 scaffolds. Conclusion: This study concluded that bone ingrowth occurred in
PCL-TCP scaffold which was transplanted with rhBMP-2, and MSCs did not affect bone growth. More sufficient
healing time would be needed to recognize effects of dMSCs on bone formation.
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INTRODUCTIONBone morphogenetic protein (BMP) was discovered by
Urist in 1965 as a growth factor that can induce bone forma-
tion. Local delivery of growth factors can induce cell proli-
feration, chemotaxis, differentiation, and matrix synthesis,
and thus, exhibits potential for regeneration.
4 Although
rhBMP can sufficiently induce bone formation by itself, its
rapid spread in the grafted site may reduce its osteoin-
ductive effect. Therefore, proper carrier systems are needed
for the delivery, maintenance and discharge of BMP to the
grafted site.
5,6
Cell source is an important element for successful tissue
renewal. Mesenchymal stem cells (MSCs) are multipotent
cells that can be differentiated into cells that make up bone
and cartilage.
7,8 In a study, an experiment on the effect of
rhBMP-2 on ectopic bone formation with absorbable
collagen sponge (ACS) and beta TCP as carriers, Kim, et
al.
9 found that the carrier for delivering BMP must be scaf-
folds, which offer bone-forming cells a space for bone
formation, and that this space must be maintained for a
considerable length of time for sufficient maturing of the
new bones.
10,11 If mechanical resistance to compressive
force transmitted through mucogingival flaps is restricted,
particularly for onlay bone graft such as alveolar ridge aug-
mentation, a space for bone formation may be maintained. 
This study was designed to investigate the provision of
space for bone formation by PCL-TCP scaffolds through
appropriate mechanical properties, the survival and proli-
feration of dMSCs in the scaffolds when a graft material
that consists of auto-fibrin glue (AFG), rhBMP-2, dMSCs,
and PCL-TCP scaffolds was placed by onlay grafting
techniques on the bone surface.
Animals
This experiment was approved by Animal Care Committee
of the College of Medicine, Korea University. Two 1.5
year-old adult beagle dogs, weighing about 12 kg, were
used in this study. 
Scaffold design and fabrication
PCL-TCP (80 : 20%) scaffolds were purchased from
Osteopore International Pte Ltd,Singapore.
The composites of the scaffold manifested a lay-down
pattern of 0/60/120
O, a porosity of about 70% and volume
measuring as 5.0×5.0×8.0 mm. 
The scaffolds were soaked for 3 h at 37.1˚C in phos-
phate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) prior to
rhBMP-2 seeding.
Bone morphogenetic protein
Ten µg of recombinant human BMP-2 (rhBMP-2) (Cowel-
lmedi Co, Busan, Korea) was used at concentrations of 50
µg/mL on each block containing rhBMP-2, and four experi-
mental groups were made (Table 1). Ten µL of rhBMP-2
was mixed with 190 µL of auto-fibrin glue, which was
evenly pipette-loaded on each scaffold
MSCs isolation and cultivation 
dMSCs were isolated from 10 mL of the canine marrow
aspirates using a modification of techniques previously
established for human MSCs (hMSCs) and incubated three
weeks before grafting surgery. 
Making of auto-fibrin glue 
Ten mL of blood collected from the beagle dog was anti-
coagulated (3.8% sodium citrate) to obtain plasma. After
two cycles of thawing and freezing, the plasma was
centrifuged at 2,500 r.p.m. for 40 minutes to obtain white
sediments, which were used to make solution A. Solution
B was prepared by mixing commercial bovine thrombin
100 IU and 2% calcium chloride. Fibrin curd was obtained
after 10 to 15 seconds using equal quantities of solutions A
and B. To prepare auto serum gel before grafting, solution
A was mixed with cells (2×10
7 cells/mL) stained with
PKH26 (Sigma-Aldrich, Inc., St. Louis, MO, USA), and
100 µL each of solutions A and B were injected to the
PCL-TCP scaffolds. After this procedures, the BMP-2 was
added.
Surgical techniques
Each beagle dog was given the premedication, atropine
sulphate (0.05 mg/kg), and anesthesia was induced with
Zoletil (5 mg/kg) and isoflurane. The general anesthetic
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MATERIALS AND METHODS
Table 1.Four Experimental Groups Used in This Study 
Group Composition of four experimental group 
Group 1 PCL-TCP-fibrin glue composites (control)
Group 2 PCL-TCP-fibrin glue-dMSC composites
Group 3 PCL-TCP-fibrin glue-dMSC composites with rhBMP-2
Group 4 PCL-TCP-fibrin glue-dMSC composites rhBMP-2 + PCL membrane
PCL-TCP, Polycaprolactone-tricalcium phosphate; dMSC, dog mesenchymal stem cell; rhBMP-2, recombinant humen bone morphogenetic 
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was delivered and monitored under the supervision of an
experienced veterinarian. 
To expose the scapular bone, the skin, subcutaneous part
and muscles around the scapular origin were cut out. An
orthopedic bur was used to remove the cortical bone to
match the PCL-TCP scaffolds (5.0×5.0×8.0 mm). After
placing the grafted material in the defect, the grafted
material was fixed by orthodontic mini-implant, Dual-top
®
(titanium alloy, Jeil Co., Seoul, Korea). 
Wound closure was carried out in layers (subcutaneous,
muscle, and skin) using a silk suture that ensured complete
coverage of the scapular bone. The graft materials were
placed and fixed separately in BMP groups (G3, G4) and
non-BMP groups (G1, G2) around the scapular origin.
(Fig. 1.)
Staining tissue samples
At 2 and 4 weeks after implantation, each dog was
anesthetized, followed by euthanasia via perfusion with
formalin through the left ventricle of the heart. 
The sampled tissues were divided into two parts. One
half was stained with hematoxylin/eosin (H-E), and the
other half was checked with a fluorescence microscope for
the survival and proliferation of the dMSCs cells that had
been injected. The survival of the dMSCs that had been
stained by PKH26 was assessed histologically. Von-Kossa
staining was used, depending on the degree of matrix
formation of the tissues. The tissues were observed at
magnification ×40 and ×100. 
The surgical sites healed well; and there were no comp-
lications or inflammation. 
Removal  resistance 
Non-BMP groups (G1 and G2) were easily removed from
the scapular bone bed after the mini-implant for fixation
was removed at both time points. BMP groups (G3 and G4)
exhibited some resistance at week 2, but separated at week
4 when the graft materials adhered completely to the
scapular bone while a part of the graft materials remained
in the scapular bone (Fig. 2). This remaining graft material
was harvested and stained.
Histological observation
Histologically, new bone was found to grow in the scaffolds
near the scapular bone at two weeks (Figs. 3 and 5). The
tissues collected at weeks 2 and 4 showed that the PCL-
20% TCP scaffolds were clinically observed to maintain
their shape without deformation which might possibly be
due to the pressure of soft tissues such as surrounding
muscles. Histological observation also revealed that the
injected cells were proliferating well in the G2, G3, and G4
scaffolds (Figs. 3 and 4). 
When compared to G1 and G2, this phenomenon can be
seen as a bone formation accelerating effect of rhBMP-2
RESULTS
Fig. 1. Position of graft materials in both scapular bones. PCL-TCP scaffold in
size 5.0×5.0×8.0 mm was used, and the grafted material was fixed by
orthodontic mini-implant. PCL-TCP, Polycaprolactone-tricalcium phosphate.
Fig. 2. Specimens taken 2 weeks after grafting. Grafts G1 and G2 (the non-BMP group) were easily detached from the recipient beds, whereas
grafts G3 and G4 (the BMP group) were difficult to detach due to the bone-like tissue at the junction of the scaffolds and the scapular bone. BMP,
bone morphogenetic protein.
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Fig. 5. Light micrographs of the specimens taken 2 weeks after grafting. Active cell proliferation was observed in the scaffolds of all groups. Bone
formation from the area adjacent to the scapular bone was noted in grafts G3 and G4 (the BMP group) (H-E stain, original magnification ×40).





Fig. 4.Fluorescence micrographs of the specimens taken 4 weeks after grafting. Cellular proliferation was more active in the grafts without rhBMP-
2 (G2) than in those with it (G3). rhBMP-2, recombinant human bone morphogenetic protein-2.
G2 G3
Fig. 3. Light and fluorescence micrographs of the specimens taken 2 weeks after grafting. (A) Light micrograph shows that calcium is deposited in
the bone matrix of grafts G3 and G4 (Von-Kossa stain, original magnification ×100). (B) Fluorescence micrograph reveals that dMSCs which are
stained with PKH26 survive (fluorescence stain, original magnification ×100). dMSC, dog mesenchymal stem cell.
G3 G4on the host bone. The survival and proliferation of dMSCs
that had been fluorescent-stained could be observed in the
G2, G3 and G4 tissues at weeks 2 and 4. More dMSCs
were observed at week 4 than at week 2. However, while
survival and proliferation of the grafted cells were observed
at weeks 2 and 4 after tissue collection in G2, which
consisted of dMSCs graft materials, little sign of bone
formation was observed in H-E stained or Von-Kossa
stained samples. More bone formation was observed in the
graft materials at week 4 than at week 2 in G3 and G4,
however, less bone formation was observed in G1 and G2
(Figs. 5 and 6) . Calcium deposition was observed in the
bone matrix by Von-Kossa stains of G3 and G4 tissues. 
The main purpose of this pilot study was to find a means
of accelerating bone formation, to obtain the following
basic data for application in the facial bone, and to answer
the following questions. 
1. Is the application of PCL-TCP and dMSCs effective in
bone formation? 
2. Is autologous fibrin effective in grafting dMSCs? 
3. Does the application of rhBMP-2 accelerate bone
formation? 
The PCL-20% TCP scaffold used in this experiment was
reported to be a effective material in bone tissue ing-
rowth,
12,13 and showed osteoblast proliferation, differen-
tiation, and mineralized tissue formation. Furthermore, the
degradation behavior and bioactive nature
14 of this scaffold
and its effect as a delivery system for BMP-2 and
15 PRP
16
have recently been reported. This scaffold has sufficient
physical properties to withstand both wound contraction
force and load bearing applications, unlike ACS, hyaluronic
acid based hydrogel, or polylactic acid which are currently
used in bone tissue engineering. This scaffold can prevent
the use of titanium reinforced e-polytetrafluoroethylene (e-
PTFE) for vertical ridge augmentation in the oral cavity, as
well as secondary removal or complications following
augmentation.
17 Rah concluded that porous scaffold was a
safe and effective bone substitute for contouring the facial
skeleton.
18 Slow degradation provides space for bone
formation by ensuring that bone forming cells and growth
of the new bone in scaffolds occur over a considerable
length of time. The PCL scaffolds in this study worked as
we expected and it seemed to withstand the forces.
The bone marrow MSCs are ideal cell sources for tissue
engineering of the maxillofacial region for a few reasons.
They pose no ethical or legal problems, are easy to get and
use, have a wide-ranging self-proliferation abilities, can be
easily differentiated to a desired cell type, and present
Effects of PCL-TCP, rhBMP-2 and dMSCs on Bone Formation: Pilot Study in Dogs
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DISCUSSION
Fig. 6. Light micrographs of the specimens taken 4 weeks after grafting. Bone formation was not observed in grafts G1 and G2. However, in grafts





G2almost no possibility of immune response or tumorige-
nesis.
19 Whether the cells used in this experiment were
actual stem cells or not could not be assured, because
dMSCs were obtained by an ordinary method and not
confirmed by specific markers. The lack of bone formation
observed in both G1 and G2 may be due to the short period
of observation and there exists the possibility that stem
cells differentiated to cells other than osteoblasts. BMPs
play an important role in bone formation and skeletal
development.
20 BMP is a differentiation factor, and promotes
the flow of MSCs into a fractured area and differentiation
of bone and cartilage forming cells.
21 BMPs stimulate
angiogenic factors such as vascular endothelial growth and
fibroblast growth and promote the recruitment and activa-
tion of endothelial cells, which are required for new
vascular formation.
22 In this study, 10 µg of rhBMP-2 was
grafted together with dMSCs using the auto-fibrin as a
carrier in G3 and G4. Unlike in G1 and G2, resistance was
felt in G3 at week 2 after tissue collection, and a mass
similar to bone was found below the graft material. At
week 4, the scaffolds were completely adhered to the
scapular bone, and a part of the scaffolds remained in the
scapular bone after they were collected. However, a little
bone formation could be observed in the scaffolds. The
short period of observation and the fact that it was unclear
if the grafted cells were dMSCs may account for this.
Also, we need a control of scaffold without MSCs.
Fibrin glue is a biological adhesive that originates from
blood and acts as a barrier to homeostasis. It is known to
play an important role in the formation and infiltration of
new capillaries while acting as a scaffold that offers a
stable fibrin network for the growth of fibroblasts.
23,24 But,
this study was designed to evaluate auto fibrin’s disa-
dvantage as well, because it is reported
27 that fibrin glue
prevents bone ingrowth through controlling bone morpho-
genetic protein diffusion and bone morphogenetic protein-
stimulated bone growth. This effect may not be beneficial
for bone graft in oral cavity. Moreover, commercial fibrin
glues generally use fibrinogen extracted from the blood of
people, which carries with risks of potential diseases such
as viral hepatitis or AIDS and complications due to
immunorejection. 
Therefore, auto fibrin glue is usually recommended over
commercial fibrin glue.
25,26 In addition, fibrin glue improves
the stability and cell-attachment of delivering cells in PCL-
TCP scaffolds and the loading efficiency of rhBMP-2, and
delays rhBMP-2 release. In the present study, we used
autologous fibrin as the delivery system for auto-MSCs
and rhBMP-2 and found that autologous fibrin could be
used as an appropriate carrier for dMSCs and rhBMP-2.
Furthermore, there was difference between MSCs alone
and MSCs with osteogenic media. We found the survival
and proliferation of the grafted dMSCs without inflam-
mation by immunorejection, and better bone formation in
BMP groups than in non-BMP groups dMSCs: At weeks 2
and 4 after grafting, PCL-TCP scaffolds by AFG had more
proliferation at week 4 than at week 2. 
In conclusion, 
1. PCL-TCP can be used as a scaffold to provide sufficient
space for bone formation in the case of in vivo onlay graft.
However, more healing time is necessary to determine the
effect of MSCs in scaffolds on bone formation. 
2. Clinically, we found that PCL-TCP + AFG + dMSC
composites loaded with rhBMP-2 is the best combination
to form new bone.
3. rhBMP-2 can accelerate bone ingrowth with PCL-TCP
as a scaffold grafting to bone defects. But, MSCs do not
affect bone growth without rhBMP-2. 
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